ADUS

Addus HomeCare Corporation

Fundamental data last updated:July 26, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Care Facilities

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/03/2026

Business Summary

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. As of December 31, 2021, the company served consumers through 206 offices located in 22 states. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.

 


VALUATION

P/E

17.33

Market Cap ($M USD)

$1.75B

Forward P/E

11.91

PEG

0.26

PRICE TO SALES

1.21

PRICE TO BOOK

1.55

EV / EBITDA

11.19

5-Year Average P/E

Free Cash Flow Yield

7.87%

DCF Value

$138.67

Graham Number

$85.62

Price to FCF

12.71

EV to FCF

12.97

Earnings Yield

5.77%

FCF Yield

7.87%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$5.40

Next Year EPS Growth Estimate

$7.85

Next Year Revenue Growth Estimate

$165.43B

Return on Equity (ROE)

9.34%

FREE CASH FLOW

Operating Margin

9.82%

Debt-to-Equity

0.19

Piotroski F-Score

7

Altman Z-Score

4.68

Return on Invested Capital (ROIC)

11.05%

Current Ratio

1.83

Quick Ratio

1.83

Net Debt to EBITDA

0.22

Interest Coverage

14.39

Gross Profit margin

32.45%

FCF PER SHARE

$7.43

REVENUE PER SHARE

$78.35

Gainseekers Quantitative Analysis

Summary

The market seems to be undervaluing Addus HomeCare Corporation. With a DCF value significantly higher than recent pricing, and a Graham Number suggesting further upside, the stock appears mispriced. The Forward P/E of 12.68 and an Earnings Yield of 5.42% indicate a solid growth potential, while the robust Altman Z-score of 4.93 confirms financial stability. This combination of undervaluation and safety metrics makes it an attractive proposition for value investors.

AI Exposure / Tech Reliance

Operating in the healthcare sector, Addus HomeCare is well-positioned to leverage AI and tech advancements. As a provider of medical care facilities, integrating AI could enhance patient care and operational efficiency. The company's adaptability to tech shifts will be crucial in maintaining its competitive edge.

The Bull Case

For the value-driven investor, Addus HomeCare offers compelling reasons to buy. A strong ROIC of 11.05% and a healthy Piotroski F-Score of 7 highlight efficient capital management and operational strength. The FCF Yield of 7.39% and solid operating margins of 9.82% suggest robust cash generation and pricing power. These metrics paint a picture of a company with the ability to reinvest effectively and sustain growth.

The Bear Case

Despite its strengths, Addus HomeCare is not without risks. The Price/Book ratio of 1.65 and Price/Sales ratio of 1.28 suggest the stock may be overvalued relative to its book and sales values. Additionally, trading close to its 52-week high, the stock could face technical resistance. Investors should be cautious of potential overextension in its current valuation.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$122.00

Institutional Ownership %

1-Year Beta

0.92

Insider Buying % (6 Mo)

Distance to 52-Week High

33.05%

Distance to 52-Week Low

4.03%

EARNINGS SURPRISE %

6.58%

50-DAY SMA

$95.42

200-DAY SMA

$107.97

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.